Chaoju Eye Care Holdings Limited 朝聚眼科醫療控股有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號: 2219) 15 April 2025 Dear non-registered shareholder(s), Arrangement of Electronic Dissemination of Corporate Communications Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that ...

Core Viewpoint - Chaoyue Eye Care (02219.HK) reported a revenue of 1.405 billion RMB for the fiscal year 2024, reflecting a year-on-year growth of 2.6%, while adjusted net profit reached 203 million RMB with a net profit margin of 14.4% [1] Financial Performance - The company achieved a net cash flow from operating activities of 354 million RMB, indicating strong cash management capabilities [1] - The gross profit margin was maintained at 43.5% despite industry policy adjustments, supported by cost control and process optimization [2] - A dividend of 0.25 HKD per share was declared, with a high payout ratio of 80%, showcasing stable cash flow management [3] Business Segments - Basic ophthalmology revenue increased by 6.7% to 698 million RMB, driven by optimized diagnostic services and personalized customer engagement [1] - Consumer ophthalmology revenue slightly decreased by 0.4% to 706 million RMB, influenced by overall economic downturn, with stable pricing adjustments [1] - The number of outpatient and inpatient visits grew by 2.9% and 71.2% respectively, due to the "regional center hospital + satellite clinic" management model [1] Strategic Initiatives - The company is advancing its "North China consolidation + Yangtze River Delta breakthrough" regional strategy, operating 31 eye hospitals and 29 optical centers across seven provinces and autonomous regions [1] - Chaoyue Eye Care is enhancing its application of artificial intelligence in diagnostic processes and service efficiency [1] - The company is focusing on expanding its network through new establishments and acquisitions while strengthening its smart healthcare system [1] Market Outlook - The high demand in the ophthalmology sector is supported by an aging population and increasing myopia prevention needs among youth, which drives the demand for basic eye care services [2] - The trend of consumption upgrades is gradually releasing the market potential for high-end services such as refractive surgery [2] - The company is adapting to the policy environment through its "Excellence Program," optimizing procurement processes and enhancing service efficiency [2] Social Responsibility - In 2024, the company will enhance its social value through public welfare projects, providing amblyopia screening and treatment for underprivileged children in Inner Mongolia [2] - Participation in the "Belt and Road Brightness Action" international medical assistance and conducting over a hundred eye health awareness activities, reaching thousands of families [2] Research and Development - The company led five research projects, published 18 papers, and obtained five patents during the year, laying the groundwork for technological upgrades [3] - The "Phoenix Plan" for human resources aims to attract high-end talent and promote integrated development of science, education, and research [3] Future Focus - Management plans to concentrate on three main areas by 2025: deepening the layout in North China and the Yangtze River Delta, expanding the scope of consumer eye care services, and advancing ESG (Environmental, Social, and Governance) system construction [3]

表格類別： 股票 狀態： 新提交 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02219 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 ...

發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 截至本公告日期，本公司董事會包括董事長兼執行董事張波洲先生；執行董事張小利女士、張俊峰先生及張光弟先生；非執行董事 Richard Chen MAO先生、李甄先生及張麗女士；以及獨立非執行董事何明光先生、郭紅岩女士、李建濱先生及寶山先生。 第 2 頁 共 2 頁 v 1.1.1 第 1 頁 共 2 頁 v 1.1.1 EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 朝聚眼科醫療控股有限公司 | | 股份代號 | 02219 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度之末期股息 | | 公告日期 | ...

Financial Performance - The group's revenue increased by 2.6% from RMB 1,369.5 million for the year ended December 31, 2023, to RMB 1,405.5 million for the year ended December 31, 2024[2]. - The group's profit before tax decreased by 12.2% from RMB 299.2 million to RMB 262.7 million, with a profit before tax margin dropping from 21.9% to 18.7%[2]. - The group's net profit fell by 15.6% from RMB 220.7 million to RMB 186.2 million, resulting in a net profit margin decline from 16.1% to 13.2%[3]. - The adjusted net profit under non-IFRS decreased by 9.1% from RMB 223.1 million to RMB 202.7 million, with the adjusted net profit margin dropping from 16.3% to 14.4%[3]. - The group's gross profit margin decreased from 45.4% to 43.5%[7]. - The group's EBITDA under non-IFRS was RMB 374.1 million, slightly down from RMB 377.3 million in the previous year[7]. - The total gross profit for the group was RMB 611.3 million, a decrease of 1.6% from RMB 621.1 million in the previous year[18]. - The company's net asset value was RMB 2,326,151 thousand, down from RMB 2,378,425 thousand in 2023, reflecting a decrease of 2.2%[96]. - The company reported a significant increase in cash and cash equivalents, reaching RMB 780,785 thousand, compared to RMB 463,437 thousand in 2023, an increase of 68.4%[95]. Revenue Sources - The consumption ophthalmology services accounted for 50.3% of total revenue in 2024, making it the primary revenue source for the group[14]. - Basic ophthalmology services contributed approximately 49.6% to total revenue in 2024, serving as another major revenue source[17]. - Revenue from consumer ophthalmology services decreased by 0.4% from RMB 709.2 million to RMB 706.4 million, indicating a slowdown in the Chinese consumer market[30]. - Revenue from basic ophthalmology services increased by 6.7% from RMB 654.0 million to RMB 697.8 million, driven by enhanced marketing activities and improved patient conversion rates[31]. Operational Metrics - Outpatient visits increased to 1,137,742 in 2024 from 1,128,719 in 2023, with an average spending per visit rising from RMB 698 to RMB 713[9]. - Inpatient visits rose to 72,120 in 2024 from 67,258 in 2023, while average spending per inpatient visit decreased from RMB 7,109 to RMB 6,914[9]. - The optical center recorded 105,354 customer visits in 2024, down from 120,184 in 2023, with average sales price increasing from RMB 806 to RMB 900[9]. Dividends and Shareholder Returns - The board proposed a final dividend of HKD 0.1193 per share for the year ended December 31, 2024, down from HKD 0.2208 per share in 2023[4]. - The total interim dividend declared and paid for the six months ended June 30, 2024, was approximately HKD 90.28 million (equivalent to RMB 82.5 million)[4]. - The company has declared a final dividend of HKD 0.2208 per share and a special dividend of HKD 0.0767 per share, totaling approximately HKD 205.5 million (approximately RMB 187.1 million) for the year ended December 31, 2023[88]. Employee and Operational Structure - As of December 31, 2024, the group employed a total of 1,464 full-time medical professionals, including 296 doctors, 625 nurses, and 543 other professionals[20]. - The company has 267 registered full-time ophthalmologists as of December 31, 2024, contributing to its medical expertise[79]. - The total employee benefit expenses increased to RMB 421,240 in 2024 from RMB 377,754 in 2023, reflecting a growth of 11.5%[115]. - Employee compensation includes basic salary, performance-related bonuses, and discretionary year-end bonuses, with regular performance evaluations for salary reviews[80]. Strategic Initiatives and Future Plans - The group plans to continue expanding its network in the North China region and aims to acquire more hospitals in the near future[26]. - The company plans to invest HKD 200 million in research and development for innovative eye care solutions over the next two years[132]. - The company aims to improve operational efficiency, targeting a 5% reduction in costs by optimizing supply chain management[132]. - Future guidance indicates a potential revenue growth of 10-15% annually over the next three years[132]. Financial Position and Liabilities - The total liabilities decreased to RMB 554,765 thousand from RMB 544,381 thousand in 2023, indicating a slight increase in financial obligations[96]. - The total interest-bearing borrowings as of December 31, 2024, amounted to RMB 40,629,000, compared to RMB 7,153,000 in 2023, showing a significant increase[126]. - Trade receivables increased by 33.6% from RMB 55.7 million for the year ended December 31, 2023, to RMB 74.4 million for the year ending December 31, 2024, due to growth in basic ophthalmic services[45]. Compliance and Governance - The company has confirmed compliance with corporate governance codes and standards since January 1, 2024[67]. - The audit committee and independent auditors confirmed that the annual performance for the year ending December 31, 2024, complies with applicable accounting standards and regulations[84]. - The company has established an audit committee consisting of three independent non-executive directors to oversee financial reporting and risk management[70].

（於開曼群島註冊成立的有限公司） （股份代號：2219） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Chaoju Eye Care Holdings Limited 朝聚眼科醫療控股有限公司 (1) 聯席公司秘書辭任； (2) 委任聯席公司秘書；及 (3) 豁免嚴格遵守上市規則第3.28及8.17條 I. 聯席公司秘書辭任 朝聚眼科醫療控股有限公司（「本公司」，連同其附屬公司統稱為「本集團」）董事（「董 事」）會（「董事會」）謹 此 宣 佈，解 淳 女 士（「解女士」）已 辭 任 本 公 司 聯 席 公 司 秘 書（「聯席公司秘書」），自 二 零 二 五 年 三 月 十 七 日 起 生 效，以 投 放 更 多 時 間 處 理 其 他 事 務。 解 女 士 確 認，其 與 董 事 會 概 無 任 何 意 見 分 歧，亦 無 其 他 ...

朝 聚 眼 科 醫 療 控 股 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱 為「本集團」）董 事（「董 事」）會（「董事會」）謹 此 公 佈，董 事 會 會 議 將 於 二 零 二 五 年 三 月 二 十 六 日（星 期 三） 舉 行，藉 以（其 中 包 括）考 慮 及 批 准 本 集 團 截 至 二 零 二 四 年 十 二 月 三 十 一 日 止 年 度 之 全 年 業 績 及 其 發 佈，並 考 慮 建 議 派 發 末 期 股 息（如 有）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Chaoju Eye Care Holdings Limited 朝聚眼科醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2219） 董事會會議日期 承董事會命 朝聚眼科醫療控股有限公司 主 席 張波洲 香 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Chaoju Eye Care Holdings Limited 朝聚眼科醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2219） 須予披露交易 認購結構性存款產品 認購結構性存款產品 茲提述本公司日期為二零二四年八月十二日及二零二四年九月二十七日的 公 告，內 容 分 別 有 關 認 購 本 金 總 額 為 人 民 幣 20 百 萬 元（「八月存款產品」）及 人 民 幣 240 百 萬 元（「九月存款產品」）的 中 國 銀 行 結 構 性 存 款 產 品。 董 事 會 宣 佈，於 二 零 二 四 年 十 二 月 九 日，朝 聚 醫 療 科 技（本 公 司 的 間 接 全 資 附 屬 公 司）進 一 步 認 購 本 金 總 額 為 人 民 幣 150 百萬元的中國銀行結 ...

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 734,287,000, representing a 6.0% increase from RMB 692,688,000 in the same period of 2023[18]. - Gross profit for the same period was RMB 335,974,000, up 4.0% from RMB 322,922,000 year-on-year[18]. - Net profit decreased by 9.0% to RMB 133,620,000 from RMB 146,912,000 in the previous year[18]. - The adjusted net profit under non-IFRS was RMB 144,753,000, a 6.0% increase from RMB 136,539,000 in the prior year[18]. - Total comprehensive income for the period was RMB 137,972,000, down from RMB 164,608,000 in the previous year[103]. - The company's total equity as of June 30, 2024, was RMB 2,341,006,000, a decrease from RMB 2,378,425,000 at the end of 2023[105]. - The basic earnings per share for the period was RMB 0.20, unchanged from the previous year[102]. - The company reported a net profit of RMB 136,453,000 for the six months ended June 30, 2024, compared to RMB 150,613,000 for the same period in 2023, representing a decrease of approximately 9.4%[107]. Assets and Liabilities - Total assets as of June 30, 2024, were RMB 2,835,653,000, down 3.0% from RMB 2,922,806,000 at the end of 2023[19]. - Total liabilities were RMB 494,647,000, a decrease of 9.1% from RMB 544,381,000[19]. - Cash and cash equivalents decreased by 14.6% to RMB 395,734,000 from RMB 463,437,000[19]. - Trade receivables increased by 21.2% from RMB 55.7 million to RMB 67.5 million, primarily due to growth in basic ophthalmic services leading to higher medical insurance receivables[50]. - Trade payables increased by 13.0% from RMB 55.4 million as of December 31, 2023, to RMB 62.6 million as of June 30, 2024, driven by business expansion[54]. Revenue Breakdown - Revenue from consumer ophthalmology services rose by 4.3% from RMB 361.1 million to RMB 376.5 million, driven by market expansion through new hospital and optical center establishments and acquisitions[37]. - Revenue from basic ophthalmology services increased by 7.7% from RMB 331.6 million to RMB 357.2 million, attributed to enhanced marketing activities and improved patient service processes[38]. - Consumer ophthalmic services accounted for 51.3% of total revenue, a decrease of approximately 0.8 percentage points from the previous year[28]. - Basic ophthalmic services represented 48.6% of total revenue, an increase of about 0.7 percentage points compared to the previous year[29]. Operational Highlights - Outpatient visits increased to 571,087 in the six months ended June 30, 2024, from 531,714 in the same period of 2023, representing a growth of approximately 7.4%[24]. - The average spending per outpatient visit rose to RMB 764, up from RMB 752, indicating an increase of about 1.6%[24]. - The number of inpatient visits increased to 35,814, compared to 32,922 in the previous year, reflecting a growth of approximately 8.6%[24]. - The company expanded its network to 31 ophthalmology hospitals and 29 optical centers across seven provinces and municipalities in China as of June 30, 2024[23]. Strategic Initiatives - The company aims to focus more on consumer eye care services while maintaining its advantages in basic eye care services[21]. - The company believes its advanced technology and equipment will enhance brand recognition and customer loyalty, contributing to competitive advantages in myopia prevention[21]. - The company aims to strengthen its leading position in North China and enhance its market presence in key areas like the Yangtze River Delta through new hospital constructions and acquisitions[34]. - The group plans to implement a centralized management model focused on regional center hospitals to improve resource efficiency[35]. Cost and Expenses - The group's sales cost increased by 7.7% from RMB 369.8 million for the six months ended June 30, 2023, to RMB 398.3 million for the six months ending June 30, 2024, primarily due to fixed costs and expenses related to new hospital openings and upgrades[39]. - Sales and distribution expenses increased by 22.8% from RMB 51.3 million to RMB 63.0 million, driven by marketing and advertising costs associated with new acquisitions and existing hospitals[42]. - Administrative expenses decreased by 3.8% from RMB 110.6 million to RMB 106.4 million, primarily due to cost control measures[43]. Cash Flow and Investments - The net cash flow from operating activities for the six months ended June 30, 2024, was RMB 174.5 million, a decrease from RMB 194.8 million in the same period of 2023[53]. - The net cash outflow from investing activities was RMB 18.8 million, significantly improved from RMB 589.4 million in the previous year[53]. - The net cash outflow from financing activities was RMB 224.3 million, compared to RMB 153.8 million in the prior year, primarily due to dividend payments[53]. Shareholder Information - The company declared an interim dividend of HKD 0.1307 per share for the six months ending June 30, 2024, compared to no dividend for the same period in 2023[63]. - The company has 2,648 full-time employees as of June 30, 2024, including 1,458 hospital professionals and 101 optical center professionals[71]. - The company has established an audit committee to oversee financial reporting and risk management systems[66]. Future Outlook - The company plans to acquire hospitals in new markets with high demand for ophthalmic services, allocating 44.80% of the net proceeds for this purpose[68]. - Future guidance indicates a projected revenue growth of 20% for the full year 2024[162]. - The company aims to enhance its outpatient services, expecting a 25% increase in patient visits by mid-2025[162].

Revenue Growth - The group's revenue increased by 6.0% from RMB 692.7 million in the same period of 2023 to RMB 734.3 million for the six months ended June 30, 2024[2]. - The group's revenue increased by 6.0% from RMB 692.7 million for the six months ended June 30, 2023, to RMB 734.3 million for the six months ended June 30, 2024, primarily due to acquisitions of ophthalmology hospitals and optical centers[8]. - Revenue from consumer ophthalmology services rose by 4.3% from RMB 361.1 million to RMB 376.5 million, driven by market expansion and the introduction of new hospitals and optical centers[21]. - Revenue from basic ophthalmology services increased by 7.7% from RMB 331.6 million to RMB 357.2 million, supported by enhanced marketing activities and improved patient service processes[22]. - Revenue for the six months ended June 30, 2024, was RMB 734,287 thousand, an increase of 6.0% compared to RMB 692,688 thousand for the same period in 2023[67]. - Revenue from outpatient services was RMB 436,163,000 for the six months ended June 30, 2024, compared to RMB 399,816,000 in 2023, reflecting an increase of 9.1%[87]. Profitability - Gross profit rose by 4.1% from RMB 322.9 million to RMB 336.0 million, with a gross margin decrease from 46.6% to 45.8%[2]. - Profit before tax decreased from RMB 184.6 million to RMB 179.6 million, resulting in a profit margin decline from 26.6% to 24.5%[2]. - Net profit fell by 9.1% from RMB 146.9 million to RMB 133.6 million, with a net profit margin decreasing from 21.2% to 18.2%[2]. - Basic earnings per share decreased from RMB 0.21 to RMB 0.20[3]. - Non-IFRS adjusted net profit increased by 6.1% from RMB 136.5 million to RMB 144.8 million, with an adjusted net profit margin of 19.7%[4]. - The total profit attributable to equity holders of the parent company for the six months ended June 30, 2024, was RMB 136,453,000, a decrease of 9.4% from RMB 150,613,000 for the same period in 2023[94]. Operational Metrics - The number of ophthalmology hospitals operated by the group increased from 26 to 31[3]. - Outpatient visits increased to 571,087 in the six months ended June 30, 2024, compared to 531,714 in the same period of 2023, representing a growth of approximately 7.4%[7]. - Inpatient visits increased to 35,814 in the six months ended June 30, 2024, compared to 32,922 in the same period of 2023, marking a growth of approximately 8.7%[7]. - The optical center customer visits totaled 51,774 in the six months ended June 30, 2024, down from 58,317 in the same period of 2023, a decline of approximately 11.8%[7]. - The group operates a network of 31 ophthalmology hospitals and 29 optical centers across seven provinces and municipalities in China as of June 30, 2024[6]. Cost and Expenses - The group's cost of sales grew by 7.7% from RMB 369.8 million to RMB 398.3 million, primarily due to fixed costs and expenses related to new hospital openings and renovations[23]. - Sales and distribution expenses increased by 22.8% from RMB 51.3 million for the six months ended June 30, 2023, to RMB 63.0 million for the six months ended June 30, 2024, primarily due to increased marketing and advertising costs associated with new hospital acquisitions and existing hospital activities[26]. - Administrative expenses decreased by 3.8% from RMB 110.6 million for the six months ended June 30, 2023, to RMB 106.4 million for the six months ended June 30, 2024, mainly due to cost control measures[27]. - The gross profit from consumer ophthalmic services was RMB 183.0 million, a decrease of 1.6% compared to RMB 185.9 million for the same period in 2023, primarily due to a 10.4% increase in costs[14]. - The gross profit from basic ophthalmic services for the same period was RMB 152.9 million, an increase of 11.6% compared to RMB 137.0 million in 2023, driven by a 7.7% increase in revenue and cost allocation[14]. Cash Flow and Liquidity - For the six months ended June 30, 2024, the net cash flow from operating activities was RMB 174.5 million, a decrease from RMB 194.8 million in the same period of 2023[38]. - The net cash flow used in investing activities was RMB (18.8) million, significantly improved from RMB (589.4) million year-on-year[38]. - The net cash flow used in financing activities was RMB (224.3) million, compared to RMB (153.8) million in the previous year, primarily due to dividend payments[38]. - The company’s main sources of liquidity include cash generated from operations and financing through debt and equity[37]. - The company reported a net cash outflow from financing activities of RMB 224,348,000, compared to RMB 153,764,000 in the previous year, indicating increased financing costs[74]. Market and Strategic Outlook - The Chinese ophthalmic medical services market is expected to reach RMB 223.1 billion by 2024, with the North China market projected to grow to RMB 33.7 billion[18]. - The company aims to enhance management capabilities through systematic, standardized, professional, refined, and intelligent development over the next decade[18]. - The group plans to continue expanding its network in North China and strengthen its market position in key regions like the Yangtze River Delta[19]. - The company aims to acquire hospitals in new markets with high demand for ophthalmic services, allocating HKD 716.35 million, which is 44.80% of the total proceeds[58]. - The company is investing RMB 50 million in R&D for new ophthalmic technologies, aiming to launch two innovative products by Q4 2024[102]. Employee and Talent Management - The group employed a total of 1,458 medical professionals as of June 30, 2024, up from 1,316 in 2023, including 302 doctors, 622 nurses, and 534 other professionals[15]. - The company emphasizes talent acquisition and retention, focusing on the development of young professionals to strengthen its talent pool[18]. - The company has granted a total of 13,396,724 shares under its share incentive plan to 224 employees, with 57,613,831 shares available for future grants as of June 30, 2024[62]. - The company has not experienced any significant labor disputes or strikes that would impact operations as of June 30, 2024[64]. Dividends and Shareholder Returns - The board declared an interim dividend of HKD 0.1307 per share[3]. - The interim dividend declared for each ordinary share was 13.07 HK cents, totaling approximately HKD 92,444,000, compared to no interim dividend for the same period in 2023[92]. - The company declared a final dividend of HKD 142,256,000 for the year ended December 31, 2023, compared to HKD 111,523,000 for the previous year[91]. Compliance and Governance - The independent auditor has reviewed the interim financial results, confirming compliance with applicable accounting standards and regulations[65]. - The company has established an audit committee consisting of three independent non-executive directors to oversee financial reporting and internal controls[56]. - The company has adopted a standard code for securities trading by directors, confirming compliance since January 1, 2024[55].